H2020Индивидуална стипендия2021–2023

scGATA2track · Single cell tracking of malignant transformation in GATA2 deficiency

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2021-09-01 → 2023-08-31
Финансиране от ЕС: 160 932 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Генетичният дефицит на GATA2 и превръщането на здрави клетки в ракови се анализират чрез проследяване на мутации в стволови клетки. Това помага за разбирането на молекулярните механизми на заболяването, за да се създадат по-добри инструменти за прогнозиране на развитието му.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Single cell tracking of malignant transformation in GATA2 deficiency

Precision medicine has improved overall survival of cancer patients; unfortunately, not all diseases can benefit from this practice due to a scarce understanding of their molecular mechanisms. This is the case of GATA2 deficiency, a complex multi-system disorder characterized by bone marrow failure, immunodeficiency and high risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Chemotherapy and allogenic hematopoietic stem cell (HSC) transplantation are the only available treatments, underlining the lack of predictive tools as a clear medical need. Penetrance and expressivity within GATA2 families is often variable, suggesting that cooperating somatic mutations and epigenetic events are required to trigger the disease. I propose to unravel the molecular mechanisms of malignant progression of GATA2 deficiency by combining multi-OMIC approaches with groundbreaking functional assays in human induced pluripotent stem cells (hiPSCs). First, to identify pathogenic single nucleotide variations and small insertion-deletions, I have performed an integrative analysis combining whole exome sequencing with DNA methylation on 16 well-annotated GATA2 carriers. Then, I have modelled the stepwise progression of normal cells to MDS through the sequential introduction of recurrent GATA2 mutations and known second driver mutations in hiPSCs by CRISPR/Cas9 genome editing. The hiPSC-derived hematopoietic progenitors have been used for transcriptomic profiling and the chromatin accessibility profiling is still ongoing to decipher the underlying gene regulatory networks among the different genetic backgrounds. Objectives: 1. Evaluate the genetic/epigenetic status of GATA2deficient patient samples. 2. Elucidating the functional consequences of recurrent GATA2 itself and driver mutations in human-based disease models. 3. Unraveling the clonal hierarchy of genomic aberration in GATA2 deficiency patients

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Precision medicine has improved overall survival of cancer patients; unfortunately, not all diseases can benefit from this practice due to a scarce understanding of their molecular mechanisms. This is the case of GATA2 deficiency, a complex multi-system disorder characterized by bone marrow failure, immunodeficiency and high risk to develop myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Chemotherapy and allogenic hematopoietic stem cell (HSC) transplantation are the only available treatments, underlining the lack of predictive tools as a clear medical need.Penetrance and expressivity within GATA2 families is often variable, suggesting that cooperating somatic mutations and epigenetic events are required to trigger the disease. Here I propose to unravel the molecular mechanisms of malignant progression of GATA2 deficiency by combining single cell multi-OMICs approaches with groundbreaking functional assays in human induced pluripotent stem cells (hiPSCs). First, to identify pathogenic single nucleotide variations and small insertion-deletions, I will perform an integrative analysis combining whole exome sequencing with whole-genome bisulfite sequencing to analyze the methylation status genome wide on 15 well-annotated GATA2 carriers. Then, I will model the stepwise progression of normal cells to MDS through the sequential introduction of recurrent GATA2 mutations and known second driver mutations in hiPSCs by CRISPR/Cas9 genome editing. The hiPSC-derived hematopoietic progenitors will be used for simultaneous profiling of transcriptome and chromatin accessibility at single cell resolution to decipher the underlying gene regulatory networks among the different genetic backgrounds.A thorough understanding of the genetic and epigenetic features of GATA2 carriers and the transcriptional dynamics during cancer initiation/progression will provide valuable insight into early detection and the design of novel personalized therapeutic strategies.

Оригинален текст от CORDIS (на английски).

Участници

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE · L'Hospitalet De LlobregatКоординаторИспания